What do survival rates actually mean for your diagnosis?

The five-year relative survival rate compares the proportion of people with a specific cancer who are alive five years after diagnosis to the proportion expected to be alive in the general population of the same age, sex, and race. A rate of 99% does not mean 1% of patients die from the cancer. It means the diagnosed group's survival is 99% of what would be expected without the cancer. It is always a backward-looking population statistic. Source: NCI SEER Program, seer.cancer.gov.

Cancer stage describes how far the disease has spread at diagnosis. Localised means confined to the organ of origin. Regional means it has spread to nearby lymph nodes. Distant (metastatic) means it has reached other parts of the body. Survival rates differ dramatically because localised cancers are generally more treatable with surgery, radiation, or targeted therapy. For example, localised lung cancer has a 64% five-year survival rate compared to just 9% for distant-stage lung cancer. Source: NCI SEER 2014-2020.

No. Survival rates are population-level statistics, not individual predictions. They describe what happened to large groups of people diagnosed in previous years. Your individual outcome depends on many factors: tumour biology, genetic markers, treatment response, overall fitness, comorbidities, and access to care. Two people with the same cancer type and stage can have very different outcomes. These numbers provide context for informed conversations with your oncologist, not a forecast. Source: American Cancer Society, cancer.org.

Three factors drive this. First, the pancreas sits deep in the abdomen with no reliable screening test, so most cases are diagnosed at the distant stage when surgery is no longer possible. Second, pancreatic tumours are biologically aggressive and resistant to many standard chemotherapy regimens. Third, symptoms like back pain, weight loss, and jaundice often mimic other conditions, delaying diagnosis. Localised pancreatic cancer has a 44% five-year survival rate, underscoring how much early detection matters. Source: NCI SEER; American Cancer Society.

Modern cardiac surgery has become remarkably safe. Isolated coronary artery bypass grafting (CABG) carries an in-hospital mortality rate of approximately 1-2% according to the STS National Database. Aortic valve replacement runs 2-3.5%, and combined procedures are higher at 3.5-6%. These are national averages. Individual risk depends heavily on age, emergency status, ejection fraction, kidney function, and whether the surgery is a first operation or a reoperation. High-volume surgical centres consistently outperform low-volume ones. Source: STS Adult Cardiac Surgery Database.

Yes, significantly. In-hospital sepsis mortality rises steeply with age. Adults aged 18-44 have a mortality rate of roughly 6-8%, while those aged 85 and older face 40-50% mortality. This gradient reflects declining immune resilience and higher burden of chronic conditions in older adults. Speed of recognition and treatment is the single most important modifiable factor: each hour of delay in antibiotic administration increases mortality measurably. Source: Rhee et al., JAMA 2019; Surviving Sepsis Campaign 2021 guidelines.

Yes, though the gap has narrowed considerably over the past two decades. For most common cancers, US five-year survival rates are modestly higher than UK rates. Contributing factors include earlier average stage at diagnosis in the US, faster access to newer treatments, and differences in data collection methodology. The UK has invested heavily in early diagnosis initiatives, and for cancers like breast and melanoma, UK survival now approaches US levels. Source: Cancer Research UK; Allemani et al., Lancet 2018 (CONCORD-3 study). A survival rate comparison table is available on the health statistics page.

The NCI SEER Program publishes updated survival statistics annually, typically in the spring via the SEER Cancer Statistics Review. Each update incorporates the most recent year of complete follow-up data. Because five-year survival requires five years of observation, the latest statistics always reflect diagnoses from several years prior. Cancer Research UK updates its statistics annually based on Office for National Statistics data. This calculator is refreshed within 30 days of each major data release. Source: NCI SEER; Cancer Research UK.

SEER covers approximately 48% of the US population across 22 geographic areas and is considered the most reliable cancer surveillance programme in the United States. Data quality is high because it draws from population-based cancer registries rather than voluntary hospital reporting. However, SEER data has a built-in time lag: the most recent five-year survival figures reflect patients diagnosed several years ago. Treatments improve continuously, so current survival for many cancers is likely better than published figures suggest. SEER does not capture every variable that affects survival, such as the specific treatment received or patient fitness level, which are important individual factors. Because of this, the same SEER statistic may understate survival for a patient receiving cutting-edge targeted therapy and remain accurate for a patient receiving standard-of-care treatment. Clinicians often supplement SEER data with nomograms and institutional outcome data for individual counselling. The figures on this page represent the best available population-level evidence for informational purposes. (Source: NCI SEER Program. Program overview and methodology. seer.cancer.gov.)

The word "relative" distinguishes this metric from "observed" or crude survival. Observed survival simply counts who is alive after five years, regardless of the cause of death. Relative survival adjusts for expected mortality from all other causes using life tables for the general population matched by age, sex, and calendar year. This adjustment is critical for cancers that primarily affect older adults. For example, an 80-year-old diagnosed with localised prostate cancer has a meaningful probability of dying from heart disease or another age-related condition within five years. Relative survival isolates the survival impact attributable to the cancer itself rather than to background mortality. Without this adjustment, survival rates for cancers of the elderly would look artificially low compared to cancers of younger adults. A relative survival rate above 100% is occasionally reported and indicates that, for some reason, people with that cancer type are actually surviving longer than the general population of the same age, which can occur in cancers caught through screening where the screened population is generally healthier. (Source: NCI SEER Program. Relative survival methodology. seer.cancer.gov.)